Results 61 to 70 of about 48,869 (270)
Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years
Pharmaceuticals, 2022 Influenza outbreaks caused by A/H7N9 viruses have occurred since 2013. After 2016, A/H7N9 influenza viruses underwent evolutionary changes. In this study, we examined the antigenic properties of influenza neuraminidase (NA) of A/H7N9 viruses as part of a
Yulia Desheva +7 more
doaj +1 more source
Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles
Advanced NanoBiomed Research, EarlyView.This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley +1 more source
Influenza Neuraminidase: Underrated Role in Receptor Binding
Trends in Microbiology, 2019 Summary: Influenza virus neuraminidase cleaves sialic acid groups from cell glycoproteins, enabling release of the virus from host cells. Neuraminidase also contributes to virus binding to the sialic acid groups of cell glycoproteins, which could ...
Feng Wen, X. Wan
semanticscholar +1 more source
Molecules, 2022 An epidemic of avian type H7N9 influenza virus, which took place in China in 2013, was enhanced by a naturally occurring R294K mutation resistant against Oseltamivir at the catalytic site of the neuraminidase.
Edita Sarukhanyan +2 more
doaj +1 more source
Oseltamivir drug‐disease modelling in infants with influenza virus infection
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Oseltamivir is a commonly used neuraminidase inhibitor for treatment of influenza infection, but little data exist regarding concentration‐response relationships. Methods Pharmacokinetic (PK) and viral dynamic data from an earlier NIAID Collaborative Antiviral Study Group trial in paediatric patients with influenza from 0–23 months of age
Kun Wang +4 more
wiley +1 more source
The role of influenza neuraminidase transmembrane domain on budding and virus morphology [PDF]
, 2014 Influenza A virus neuraminidase (NA), a type II transmembrane glycoprotein plays a role in the cleavage of sialic acids and facilitating the release of mature virions from the surface of infected cells. NA has also previously been shown to play a role in
Roddy, Scott, Edward
core
Nature Microbiology, 2017 A substantial proportion of influenza-related childhood deaths are due to infection with influenza B viruses, which co-circulate in the human population as two antigenically distinct lineages defined by the immunodominant receptor binding protein ...
Teddy J. Wohlbold +12 more
semanticscholar +1 more source
Current Approaches for Diagnosis of Influenza Virus Infections in Humans
Viruses, 2016 Despite significant advancement in vaccine and virus research, influenza continues to be a major public health concern. Each year in the United States of America, influenza viruses are responsible for seasonal epidemics resulting in over 200,000 ...
Sai Vikram Vemula +5 more
doaj +1 more source
Inherent Serum Inhibition of Influenza Virus Neuraminidases
Frontiers in Veterinary Science, 2021 Influenza virus vaccines have been designed for human and veterinary medicine. The development for broadly protective influenza virus vaccines has propelled the vaccine field to investigate and include neuraminidase (NA) components into new vaccine ...
Amanda L. Skarlupka +2 more
doaj +1 more source
BMEMat, EarlyView.A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang +8 more
wiley +1 more source